Fostemsavir: all 21 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentRecruitingNCT07393659Phase 3
- Reducing Systemic Inflammation in People on Antiretroviral TherapyRecruitingNCT07030920Phase 2
- Attachment Inhibitor Comparison in Heavily Treatment Experienced PatientsActive, not recruitingNCT02362503Phase 3Results posted
- HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) InfectionsCompletedNCT01384734Phase 2Results posted
- A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVActive, not recruitingNCT07053384Phase 1
- Changes in Immunologic Parameters Following the Addition of Fostemsavir in Virologically Suppressed Immunologic Non-responders Living With HIV-the RECOVER StudyActive, not recruitingNCT05220358Phase 4
- Low-dose Fostemsavir Extended Release Relative Bioavailability StudyCompletedNCT04757974Phase 1
- Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral ResistanceActive, not recruitingNCT04648280Phase 1/2
- A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy SubjectsCompletedNCT02859259Phase 1
- Absolute Bioavailability of BMS-626529 After Oral and Intravenous DosingCompletedNCT02805556Phase 1
- A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)CompletedNCT02674581Phase 1
- A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy SubjectsCompletedNCT02666053Phase 1
- A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/NaloxoneCompletedNCT02666001Phase 1
- Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release TabletCompletedNCT02508064Phase 1
- A Open-label, Drug-Drug Interaction With Maraviroc (DDI)CompletedNCT02480894Phase 1
- A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)CompletedNCT02480881Phase 1
- Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy SubjectsCompletedNCT02467335Phase 1
- Study on PharmacokineticsCompletedNCT02234882Phase 1
- Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529CompletedNCT02164045Phase 1
- Drug-drug Interaction (DDI) RifabutinCompletedNCT02138084Phase 1
- DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)CompletedNCT02063360Phase 1